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Targeted drug deliveryG protein-coupled receptors are expressed on the surface of eukaryotic cells and internalise in response
to ligand binding. The actions of the hormone and neurotransmitter neurotensin (NT) are predominantly
mediated by specific interactions with one such receptor, neurotensin receptor 1 (NTS1), which is upreg-
ulated in a variety of cancers, including pancreatic and breast tumours. NTS1 could therefore serve as a
target for selective delivery of therapeutics. This study characterised the expression of NTS1 in HEK293
cells, as well as both polarised and non-polarised intestinal epithelial Caco-2 cells. NT-conjugated fluo-
rophores were internalised in NTS1-expressing HEK293 and Caco-2 cells in a receptor-mediated fashion.
Confocal microscopy revealed fluorophore localisation in the perinuclear region. Cell uptake and trans-
port across the Caco-2 intestinal model of two NT-conjugated fluorophores (GFP and fluorescein) were
compared to evaluate the effect of cargo size on cellular uptake. This work demonstrates that NT ligand
conjugation is able to deliver relatively large macromolecular cargoes selectively into cells overexpress-
ing NTS1 and the system is able to effectively translocate macromolecules across an intestinal epithelial
model. NTS1 therefore shows potential as a drug delivery target not only for targeted but also non-
invasive (oral) delivery of biotherapeutics for cancer.
 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Targeted delivery of therapeutics to diseased tissue as a means
of increasing the therapeutic benefits of a drug, including reduction
of adverse effects [1], is a key aim of modern pharmaceutics. A
range of options are available to guide the drug to the cells or tis-
sue of interest, exploiting disease-induced changes in biology as a
basis for selectivity. Aberrantly or overexpressed cell-surfacereceptors offer an attractive route for targeted drug delivery in can-
cer [2]. Neurotensin (NT) is a tridecapeptide known to exert a vari-
ety of effects; it has a dual role as both a neuromodulator in the
central nervous system and as a local hormone in the periphery
[3]. The actions of NT are mediated by specific interactions with
one of three receptors, the first two being G protein-coupled recep-
tors (GPCRs): NTS1, NTS2 and NTS3, all of which are known to
internalise upon interaction with NT [4]. NTS1 is thought to play
the predominant role in eliciting the actions of NT and is the main
focus of this study. NTS1 is known to be upregulated in a variety of
different cancer types, including pancreatic and breast tumours [5]
and has been demonstrated to be a key driver of cell proliferation,
survival, migration and invasion (reviewed in [6]). Indeed, NTS1
antagonists have been proposed as anti-cancer agents, but
currently-available drugs exhibit significant toxicity [6].
An alternative approach to the development of such drugs is the
use of NTS1 as a molecular target for drug delivery [5–8]. The
underpinning theory is that the receptor-ligand-drug complex will
internalise, delivering drugs in a targeted manner. Initial studies
demonstrated the viability of this approach (reviewed in [6]) and
the potential of NT as a drug delivery ligand has been documented
recently. Jia et al. [9] investigated the rates of internalisation of NT
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acid (DOTA), used for radiotherapy. This study found that the use
of a spacer (b-Alanine) between NT and DOTA increases the inter-
nalisation rates of NT analogues, mediated by NTS1, compared to
conjugation without a spacer. This reflects the work of Antunes
et al. [10] that documents the effect of spacers between somato-
statin analogues and radiolabelled DOTA. Other work has used syn-
thetic oligobranched NT conjugates to deliver cargoes to cells,
including doxorubicin-loaded liposomes [11] and methotrexate
or gemcitabine [12], as well as oligobranched NT derivatives to tar-
get NT receptors [12–14]. However, little is known of the molecular
mechanism underpinning NTS1 internalisation or the limitations
on the size and nature of cargo which can be delivered. This is of
increasing importance as many recently-developed anticancer
therapeutics are biologics.
NT provides a suitable ligand for targeted delivery as it interacts
with the NTS1 receptor with high affinity (Kd 0.3–1 nM) [15] and
only its six C-terminal amino acids are required for receptor bind-
ing [16], which allows covalent or translational attachment of a
variety of macromolecules to the N-terminus. In most cell types,
receptor-mediated peptide internalisation results in fusion with
lysosomes and degradation [17]. However, internalisation of NT
has been shown to follow a different route. Vandenbulcke et al.
investigated the method of internalisation of fluorescently labelled
NT (Fluo-NT) in COS-7 cells transfected with NTS1 and demon-
strated, by methods of pathway-selective inhibition (hypertonic
sucrose, potassium depletion and cytosol acidification), that NT
internalisation is mediated by clathrin coated pits [18]. Impor-
tantly, NT and NTS1 appear to separate on internalisation and
Fluo-NT was demonstrated to traffic to the transgolgi network
[18]. This provides a possible lysosome-escape route for macro-
molecules tagged with NT, mitigating lysosome degradation as
one of the key problems of intracellular drug delivery. This makes
the NT/NTS1 cell entry pathway a particularly attractive option for
therapeutic delivery. However, NT also has a short serum half-life
(minutes) but this can be mitigated by modifications to the peptide
[19,20]. In this study, we have focussed on native NT as proof of
concept due to its well-characterised biological action and the ease
of producing NT-macromolecule complexes. This allows us to char-
acterise the properties of NTS1 internalisation, but future transla-
tional work should focus on stable analogues.
Here, we demonstrate that NTS1 can be used to internalise pay-
loads of different sizes, namely a relatively small fluorophore or
macromolecular GFP. Efficient internalisation of these cargoes is
observed in HEK293 cells expressing NTS1 and this uptake is sig-
nificantly attenuated via competition with either receptor agonists
or antagonists. Importantly, we demonstrated efficient uptake into,
and transport across, an intestinal epithelial model consisting of
polarised Caco-2 monolayers, which endogenously express NTS1.
This study demonstrates for the first time that in addition to its
potential as a targeting moiety for efficient and receptor-
mediated uptake of macromolecules specifically into cells express-
ing or overexpressing its receptor(s) (e.g. cancer), NT is also able to
ferry the cargo transintestinally in a receptor-mediated fashion,
hence also demonstrating potential for oral delivery of macro-
molecules. This addresses a significant challenge in the field [21].2. Materials and methods
2.1. Materials
Caco-2 cells were obtained from the European Collection of Cell
Cultures (ECACC) and were used between passages 60–80. HEK293
cells were obtained from the American Type Culture Collection
(ATCC) and were used between passages 25–40. Dulbecco’s Modi-fied Eagles Medium (DMEM; with 4500 mg/L glucose, L-glutamine,
sodium pyruvate and sodium bicarbonate), Hank’s Balanced Salt
Solution (HBSS; with sodium bicarbonate and without phenol
red), Trypsin/EDTA solution (0.25% trypsin, 0.02% EDTA), antibi-
otic/antimycotic solution (penicillin, streptomycin and ampho-
tericin), foetal bovine serum (FBS, non-USA origin),
dimethylsulphoxide (DMSO), trypan blue solution (0.4% solution)
and poly-l-lysine (0.1% solution, mw = 70,000–15,000) were all
obtained from Sigma Aldrich (UK). DMEM was supplemented with
10% FBS and 1% antibiotic/antimycotic solution to produce com-
plete DMEM. Transwell

permeable supports of 12 mm diameter
and 0.4 lm pore size (polyester membrane) were obtained form
Corning Life Sciences (USA). Human neurotensin was supplied by
Sigma Aldrich and SR142948 (non-peptide NTS1 and NTS2 recep-
tor antagonist) were obtained from Tocris Bioscience (UK). Pro-
tease inhibitor tablets (cOmpleteTM protease inhibitor cocktail
tablets, EDTA-free) were supplied by Roche Diagnostics (USA).
2.2. Methods
2.2.1. GFP-NT and GFP synthesis
A translational fusion of His-GFP and NT was produced by
sequential PCR (AG1 and AG3, AG2 and AG4, AG2 and AG5) on a
clone of Emerald GFP to extend the C-terminus to encode NT and
the N-terminus to encode a His6 tag. The primers used are illus-
trated in Table 1. The final PCR product was digested with NdeI/
BamHI and cloned into NdeI/BamHI digested pET17 b. pET17 b-
GFP was produced by Quikchange mutagenesis using primers
AG6 and AG7 to introduce a stop codon prior to the NT coding
sequence in pET17b-GFP-NT. GFP-NT and GFP were produced by
recombinant expression in E. coli BL21(DE3) grown in LB broth
containing 100 lg/ml ampicillin, followed by cell lysis using pulsed
sonication (5 min, 5 s on, 5 s off) in 50 mM Tris, 100 mM NaCl
pH7.4 at 2 ml per litre of culture. Purification was achieved via
Immobilised Metal Affinity Chromatography using 1 ml HisTrap
HP columns (GE Healthcare Life Sciences). Briefly, the column
was equilibrated with 5 column volumes (CV) 50 mM Tris, 100
mM NaCl pH7.4 followed by sample loading. The column was then
washed with 10 CV of the same buffer also containing 50 mM imi-
dazole. Proteins were eluted using the same buffer containing 200
mM imidazole. Protein purity was assessed via SDS-PAGE and
quantitated via UV–Vis spectrophotometry. All proteins used were
>95% pure.
2.2.2. Cell culture
Caco-2 and HEK293 cell lines were routinely cultured in 75 cm2
flasks at 5% CO2, 95% relative humidity and 37 C in DMEM. Caco-2
cells were seeded on Transwell

filter at a seeding density of
1  105 per well and cultured for 21–24 days, with medium
replacement every two days. Transepithelial Electrical Resistance
(TEER) was measured to monitor Caco-2 cell growth, polarisation
and cell monolayer integrity. HEK293 cells are weakly adherent
and were therefore cultured on poly-l-lysine (0.1% w/v) coated
coverslips in 12-well plates.
2.2.3. HEK293. transfection
HEK293 cells cultured in 12-well plates were transfected using
Lipofectamine 2000 Transfection reagent and the NTS1 contain-
ing plasmid (pcDNA3.1-NTS1, cDNA.org). This procedure used
4 ll Lipofectamine and 1 lg DNA per well. Lipofectamine and
DNA (in medium) were incubated at room temperature for
60 min to form DNA-containing liposomes. Cell medium was
replaced with reduced serum media (5% FBS) and the transfection
mixture was then applied, followed by cell incubation at 5% CO2,
95% relative humidity and 37 C for 24 h before use in experiments.
Table 1
Oligonucleotide primer sequences used in this study. Primers are displayed 50 to 30
and lowercase nucleotides indicate those which are not complementary to the
template sequence.
Primer name Sequence
AG1 caccatcaccatcacATGGTGAGCAAGGGCGAGGAGCTG
AG2 ggggggcatatgcatcaccatcaccatcac
AG3 gttttcatacagttcCTTGTACAGCTCGTCCATGCC
AG4 tataacgacgcggtttgttttcatacagttcCTTGTACAGC
AG5 ccggatccttacagaatataacgacgcggtttg
AG6 GGACGAGCTGTACAAGTAAgaactgtatgaaaacaaacc
AG7 ggtttgttttcatacagttcTTACTTGTACAGCTCGTCC
E F
C D
A B
G H
I J
Fig. 1. Neurotensin 1 (NTS1) receptor immunostaining in HEK293 and Caco-2 cells.
(A) Non-transfected HEK293 cells and negative control where cell treatment with
primary anti-NTS1 antibody was omitted (B). (C) HEK293 cells transfected with 4 ll
Lipofectamine and negative control (D). (E) Non-permeabilised, differentiated (21-
day filter culture) Caco-2 cells and negative control (F). (G) Permeabilised,
differentiated (21-day filter culture) Caco-2 cells and negative control (H). (I)
Undifferentiated (2-day plastic culture) Caco-2 cells and negative control (J). Blue
staining represents cell nuclei (stained by DAPI) and green staining represents
NTS1. Immunostaining performed using rabbit, anti-human NTS1 primary antibody
and goat, anti-rabbit AlexaFluor488 secondary antibody. Scale bar = 50 lm. (For
interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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Caco-2 cells were cultured on Transwell

permeable inserts for
21 days and evaluated for monolayer integrity by TEER measure-
ments. Cell monolayers were fixed with 4% w/v paraformaldehyde
in PBS and washed 3 times with PBS. Cells were then incubated for
one hour with 1% w/v bovine serum albumin (BSA) in PBS at room
temperature as a non-specific binding blocking step. A 1:5000 dilu-
tion of the primary antibody (Rabbit Anti-Human NTS1; Sigma
Aldrich (UK)) was prepared in 1% w/v BSA in PBS, as recommended
by the supplier, and applied to fixed cell monolayers for one hour
at room temperature. Primary antibody solution was omitted for
the negative controls and cells were incubated with the antibody
diluent solution (BSA). Each monolayer was then washed thor-
oughly with PBS and incubated for one hour with goat, anti-
rabbit AlexaFluor

488 at 1:800 dilution in 1% w/v BSA/PBS. The
secondary antibody solution was then removed and cells washed
extensively with PBS. Filter inserts were then excised and mounted
on a glass slide, treating with FluoroshieldTM with DAPI mounting
medium (Sigma Aldrich (UK)).
Caco-2 cells were also immunostained as per the method above
in their undifferentiated state, following growth on 12-well plates.
Similarly, HEK293 immunostaining was conducted after culture on
12-well plates. Confocal microscopy imaging was performed using
a Leica TCS SP8 confocal microscope using constant laser gain for
DAPI and AlexaFluor488 in all immunostained sections. Where
indicated, cells were permeabilised by addition of 0.1% Triton X
100 in PBS for 20 min at room temperature, in sterile conditions.
2.2.5. Cell uptake studies
Cell uptake studies were performed in 12-well plates for undif-
ferentiated Caco-2 and HEK293 cells following 48-h culture and in
Transwell

permeable inserts for polarised and differentiated Caco-
2 monolayers. For the latter, cells were cultured on Transwell

fil-
ter inserts for 21–24 days and TEER measured before uptake stud-
ies to confirm cell monolayer polarity and integrity (typically
2000Xcm2) [22]. In both cases, cells were initially incubated
with HBSS for at least 30 min. Samples of GFP-NT, with or without
NT, SR142948, or GFP were prepared in HBSS and applied to the
cells (apical side in case of differentiated, 21-day filter culture
Caco-2 cell monolayers). Cells were incubated with the samples
for different periods between 30 min and 2.5 h. Thereafter, samples
were removed and cells washed with cold PBS, followed by cell
permeabilisation using 200 ll of 0.1% v/v Triton X-100 in protein
buffer (200 mM Tris, 50 mM NaCl with 200 ll of 1x protease inhi-
bitor stock solution; 30 min incubation). Samples were then cen-
trifuged at 17,900g and supernatant quantified by fluorescence
measurements using a Tecan Infinite

Pro 200 microplate reader
(Fluorescein excitation 490 nm, emission 525 nm; GFP excitation
488 nm, emission 509 nm).
2.2.6. Caco-2. monolayer transport studies
Differentiated Caco-2 monolayers (21-day filter culture) were
equilibrated in HBSS for at least 30 min. Cell monolayer TEERwas measured (in HBSS) prior to the transport study to ensure cell
monolayer integrity (typically 2000Xcm2; cells with
TEER < 1000Xcm2.were excluded from the study). GFP-NT (with
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different concentrations in HBSS and applied to the apical side of
the cell monolayers. A 100 ll sample of HBSS from the basal side
of the Transwell

was taken immediately after introduction of
the samples as a measure of protein transport through the mono-
layer at time 0 min. 100 ll samples were then taken every 30 min
for three hours, replacing the volume of sample taken with fresh
HBSS each time. The effective dilution was accounted for when cal-
culating concentrations. Between samples, the Transwell

plate
was returned to the incubator. Protein transport was quantified
using fluorescence as described above. TEER was measured follow-
ing the transport study to ensure cell monolayer integrity was
intact.
2.2.7. Statistical analysis
The parametric unpaired Students t-test was used to determine
statistical significance with Welsh’s correction to correct for small
data sets.
3. Results
Initial experiments focussed on characterisation of NTS1 recep-
tor expression in HEK293 and Caco-2 cells. HEK293 cells were cho-
sen as a widely-used tumourigenic model [23] and Caco-2 cells
represent the classic epithelial gutmodel [24]. Fig. 1 shows confocal
micrographs of non-transfected HEK293 cells (A and B); transfected
HEK293 cells (C and D); non-permeabilised, differentiated (21-dayFig. 2. Neurotensin 1 (NTS1) receptor immunostaining in differentiated Caco-2 cell mono
depth relative to the surface of the Transwell plate (0 lm) (B). Anti-NTS1-immonstained
of the Transwell plate (0 lm). Immunostaining performed using rabbit, anti-human NT
Overlay of images in panels A and B.filter culture) Caco-2 cells (E and F), permeabilised, differentiated
Caco-2 cells (G and H) and undifferentiated (2-day plastic culture)
Caco-2 cells (I and J). A negative control where cell treatment with
the primary antibody was omitted is shown in each scenario. The
data demonstrates a higher level of NTS1 expression in transfected
HEK293 cells (Fig. 1C) than non-transfected HEK293 (Fig. 1A) and
non-permeabilised, differentiated Caco-2 monolayers (Fig. 1E).
Dramatically reduced NTS1 expression is apparent in perme-
abilised, differentiated Caco-2 monolayers (Fig. 1G) compared to
non-permeabilised counterparts. Non-differentiated Caco-2 cells
do not express detectable levels of NTS1 (Fig. 1I).We observed qual-
itatively higher levels of NTS1 expression on the apical surface of
the differentiated Caco-2 monolayer compared to the basal surface
(Fig. 2).
F-NT uptake by non-transfected and transfected HEK293 cells
is shown Fig. 3, both quantitatively by fluorimetry and qualita-
tively by confocal microscopy. Cells were treated with F-NT alone
or in the presence of excess free NT or excess SR142948. Free NT
competitively inhibits all NT receptors, and SR142948 selectively
inhibits NTS1 and NTS2. The data shows that the uptake of F-NT
alone is greater in transfected HEK293 cells (p = 0.026; Fig. 3B)
compared to non-transfected cells (Fig. 3A), suggesting that
uptake correlates with NTS1 expression. F-NT uptake is notably
higher relative to unconjugated fluorescein. Cell internalisation
of F-NT is also dramatically reduced by the co-application of
excess free NT (also shown by confocal microscopy in
Fig. 3C and D) or SR142948.layers (21-day filter culture). (A) DAPI-stained with false-colour imaging indicating
Caco-2 monolayer with false-colour imaging indicating depth relative to the surface
S1 primary antibody and goat, anti-rabbit AlexaFluor488 secondary antibody. (C)
Fig. 3. Internalisation of NT-conjugated fluorescein in non-transfected and transfected HEK293 cells. Quantification of F-NT uptake in (A) non-transfected and (B) pcDNA3.1-
NTS1 transfected HEK293 cells. ‘F-NT’ denotes application of F-NT at 20 nM; ‘F-NT + Free NT’ denotes application of 20 nM NT-F with 2 lM free neurotensin; ‘F-NT
+ SR142948’ denotes application of 20 nM F-NT with 200 nM SR142948; ‘F’ denotes application of fluorescein at 20 nM. Error bars are representative of mean ± SD and each
data point, n = 3. Confocal microscopy images of pcDNA3.1-NTS1 transfected HEK293 after (C) incubation with 20 nM F-NT for 1 h and (D) incubation with 20 nM F-NT and
2 lM NT for 1 h. Scale bar = 50 lm.
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cells is shown Fig. 4. Cell uptake of GFP alone was also tested in
these studies to establish the levels of internalisation of GFP itself
and confirm whether cell uptake of GFP-NT is mediated by NT. The
data shows a similar pattern in non-transfected (Fig. 4A) and trans-
fected cells (Fig. 4B), with GFP-NT showing a higher uptake com-
pared to GFP and also in conditions where GFP-NT was applied
alone (without excess free NT or SR142948). However, the differ-
ence between these conditions in non-transfected cells was not
statistically significant while in transfected HEK293 cells this dif-
ference was statistically significant (p < 0.01), suggesting correla-
tion with relative NTS1 expression. Fig. 4C and D depict confocal
micrographs comparing transfected HEK293 cells treated with
GFP-NT or GFP-NT plus a 100x excess of NT. Fluorescence due to
GFP-NT was observed in areas localised around the nucleus in cells
treated with GFP-NT only and notably lower levels of fluorescence
signal were apparent in cell samples exposed to excess NT.
NT-conjugated fluorophore internalisation in undifferentiated
Caco-2 cells is shown in Fig. 5. Caco-2 cells were incubated with
F-NT (Fig. 5A) or GFP-NT (Fig. 5B) alone, GFP-NT or F-NT with
excess free NT or excess free SR142948. Cell uptake behaviour of
fluorophores alone was also performed to provide a comparison
with the internalisation of NT-conjugated equivalent. Cell uptakeof both NT-fluorophores is not affected by competitive NTS recep-
tor inhibition via free NT or excess free SR142948. The extent of
internalisation seen for each condition is comparable to the uptake
of fluorophore alone. Confocal micrographs showing this uptake
are shown in Fig. 5C and 5D for F-NT and GFP-NT, respectively
(applied without competitive inhibitors). The images show mini-
mal F-NT fluorescence (green) within the cells, suggesting limited
uptake in undifferentiated Caco-2 cells.
Cell uptake of NT-conjugated fluorophores into polarised, differ-
entiated Caco-2 monolayers is shown in Fig. 6. NT-conjugated flu-
orophore (F-NT – Fig. 6A and GFP-NT – Fig. 6B) uptake after
150 min is notably higher compared to the internalisation in the
presence of excess free NT, as well as the unconjugated fluo-
rophores. Importantly, NT-conjugated fluorophore uptake in
polarised Caco-2 cells is markedly greater to that in undifferenti-
ated cells (Fig. 5). This uptake is quantified by measurements at
30-min intervals for a total of 150 min (Fig. 6C and D). F-NT uptake
increases with incubation time up to 60 min, with a plateau appar-
ent at subsequent time points. GFP-NT entry into cells mirrors the
pattern observed with F-NT.
Following the demonstration that NT-conjugated fluorophores
are capable of internalisation in polarised Caco-2 cells, we further
probed whether these molecules are able to traverse polarised
Fig. 4. Internalisation of NT-conjugated GFP in non-transfected and transfected HEK293 cells. Quantification of GFP-NT uptake in (A) non-transfected and (B) pcDNA3.1-NTS1
transfected HEK293 cells. ‘GFP-NT’ denotes application of GFP-NT at 20 nM; ‘GFP-NT + Free NT’ denotes application of 20 nM GFP-F with 2 lM free neurotensin; ‘GFP-NT
+ SR142948’ denotes application of 20 nM GFP-NT with 200 nM SR142948; ‘GFP’ denotes application of GFP at 20 nM. Error bars are representative of mean ± SD and each
data point, n = 3. Confocal microscopy images of pcDNA3.1-NTS1 transfected HEK293 after (C) incubation with 20 nM GFP-NT for 1 h and (D) incubation with 20 nM GFP-NT
and 2 lM NT for 1 h. Scale bar = 50 lm.
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to act as a system capable of ferrying therapeutics across the
intestinal epithelium. Fig. 7 shows the apical-to-basolateral trans-
port of F-NT and GFP-NT in Caco-2 monolayers, with samples
quantified at 30-min intervals in a 180-min study. The data shows
that both F-NT (Fig. 7A) and GFP-NT (Fig. 7B) traverse Caco-2
monolayers significantly more efficiently than the respective
unconjugated fluorophores. With both F-NT and GFP-NT a
concentration-dependent effect is observed, with higher concen-
trations demonstrating larger levels of transport, as well as process
saturation with time. Another important observation to note when
comparing Fig. 7A and B is that F-NT translocated across polarised
Caco-2 monolayers at markedly higher levels than GFP-NT.4. Discussion
This work assessed whether a receptor demonstrated to exhibit
differential expression in cancerous cells can be considered as a
system that offers both targeted drug delivery to cancer and means
of enhancing macromolecular absorption across the gut epithelium
following oral administration. We utilised both transfected and
non-transfected HEK293 cells, as well as Caco-2 intestinal epithe-
lial cells as systems with different NTS1 expression profiles.
Expression of NTS1 in HEK293 cells is consistent with previousstudies [25]. NT also acts as a local hormone in the gut [3] and
hence NTS1 expression in intestinal epithelial cells is neither unex-
pected nor non-physiological [26,27]. Examining the expression of
NTS1 in transfected HEK293 cells, confocal micrographs reveal
high levels of positive fluorescence signal in cells immunostained
for NTS1 receptor (Fig. 1C). Work also showed that differentiated,
polarised Caco-2 monolayers express the NTS1 receptor (Fig. 1E).
Dramatically reduced NTS1 expression was observed following
detergent-mediated permeabilisation (Fig. 1G), which suggests
predominant NTS1 localisation in the plasma membrane rather
than intracellular membranes. We also show that the expression
of the NTS1 receptor in non-differentiated Caco-2 cells is unde-
tectable (Fig. 1I). It is not completely clear why Caco-2 cells exhibit
differentiation-dependent expression of NTS1 but these findings
correlate with observations that NT expression is increased in cells
of the villi compared to those in the crypts [28]. Differentiated
Caco-2 cells are a model of villi enterocytes and hence expression
of a cognate receptor for NT aligns with the role in gastric function
[28]. Additionally, similar findings have been reported previously
for the class B type I scavenger receptor (SR-BI) [29] and vitamin
B2 (riboflavin) transporters [30].
Comparing NT-fluorophore uptake behaviour in non-
transfected and transfected HEK293 cells (Figs. 3 and 4), the data
reveal that cell uptake levels of F-NT or GFP-NT alone are
significantly greater in transfected HEK293 cells compared to
Fig. 5. Uptake of NT-conjugated fluorophores in undifferentiated (2-day plastic culture) Caco-2 cells. Quantification of cell internalisation of (A) F-NT and (B) GFP-NT. ‘F-NT’
denotes application of 20 nM F-NT, ‘F-NT + Free NT’ denotes application of 20 nM F-NT with 2 lM free NT, ‘F-NT + SR142948’ denotes application of 20 nM F-NT with 200 nM
SR142948, ‘F’ denotes application of 20 nM Fluorescein. ‘GFP-NT’ denotes application of 20 nM GFP-NT, ‘GFP-NT + Free NT’ denotes application of 20 nM GFP-NT with 2 lM
free NT, ‘GFP-NT + SR142948’ denotes application of 20 nM GFP-NT with 200 nM SR142948, ‘GFP’ denotes application of 20 nM GFP. Error bars are representative of
mean ± SD,n = 3. (C) Confocal micrograph showing F-NT internalisation after incubation with 20 nM F-NT for 1 h. (D) GFP-NT internalisation following incubation with 20 nM
GFP-NT for 1hr. Scale bar = 50 lm.
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was even higher in transfected cells, it is likely that a cellular pro-
cess downstream of ligand-receptor interactions reaches satura-
tion e.g. receptor internalisation. Uptake of NT-conjugated
fluorophores was rapid before eventual saturation. NTS1 appears
to be degraded following internalisation [18] and is regenerated
on the cell surface via de novo synthesis [5]. Although precise mea-
surements of NTS1 expression in native tissue have not been
reported, GPCR levels on the cell surface are typically in the order
of 1  103–1  104 molecules/cell. Therefore, sufficient uptake of
NT-conjugated molecules is potentially possible to enable delivery
of macromolecules to therapeutically sufficient levels, especially
considering the large surface area of the intestinal epithelium.
Although limited expression of other neurotensin-binding recep-
tors may occur in the cell models used, the increases in uptake
observed following NTS1 overexpression confirm that this receptor
is a viable target for drug uptake; it has been demonstrated that
NTS2 expression is undetectable in HEK293 cells [25]. Competitive
NTS1 receptor inhibition with excess free NT or excess SR142948
produced a clear inhibition of uptake in both transfected and
non-transfected HEK293 cells, while with GFP-NT this inhibition
was only apparent in transfected HEK293 (a statistically significant
inhibition was not apparent in non-transfected HEK293 cells,
although qualitative differences are evident). Inhibition of uptake
by excess ligand in transfected HEK293 cells was also confirmed
by confocal microscopy. These data therefore point to NTS1receptor-mediated uptake of NT-conjugated fluorophores in trans-
fected HEK293 cells. The competitive inhibition by NT and
SR142948 of uptake of NT-conjugated fluorophores is likely to be
bimodal. Firstly, a direct steric competition at the NT-binding site
of NTS1 [15] and, secondly, receptor internalisation which removes
receptors from the cell surface [5].
NT-conjugated fluorophore internalisation by undifferentiated
Caco-2 cells is limited (as shown both quantitatively and by confo-
cal microscopy in Fig. 5) and comparable to the uptake of fluo-
rophore alone. Furthermore, competitive receptor inhibition did
not achieve a reduction in NT-conjugated fluorophore uptake in
undifferentiated Caco-2 cells. These data collectively imply that
in undifferentiated Caco-2 cells any entry of NT-conjugated fluo-
rophores is limited and takes place via a mechanism other than
NTS receptor mediated internalisation. This is in line with the find-
ing that NTS1 expression was below detectable limits in undiffer-
entiated Caco-2 cells, confirming the system’s ability to
specifically delivery therapeutic payloads predominantly in cells
expressing NTS1 receptor. On the other hand, polarised Caco-2
monolayers demonstrated uptake of both NT-conjugated fluo-
rophores (F-NT and GFP-NT; Fig. 6), at significantly higher levels
compared to that in undifferentiated cells and the unconjugated
fluorophores and the internalisation of NT-conjugated fluo-
rophores is markedly reduced following competitive receptor inhi-
bition. Differentiated, polarised Caco-2 monolayers, which unlike
non-differentiated counterparts clearly express NTS1, are therefore
Fig. 6. Uptake of NT-conjugated fluorophores in differentiated Caco-2 cell monolayer (21-day filter culture). Quantification of cell internalisation of (A) F-NT and (B) GFP-NT
150 mins after fluorophore application. Time-dependent uptake of NT-conjugated fluorophores (C) F-NT and (D) GFP-NT. ‘F-NT’ denotes application of 100 nM F-NT, ‘F-NT
+ Free NT’ denotes application of 100 nM F-NT with 10 lM free NT, ‘F’ denotes application of 100 nM Fluorescein. ‘GFP-NT’ denotes application of 100 nM GFP-NT, ‘GFP-NT
+ Free NT’ denotes application of 100 nM GFP-NT with 10 lM free NT, ‘GFP’ denotes application of 100 nM GFP. Data points are representative of the mean of n = 3
independent experiments and error bars are representative of ± standard deviation (SD).
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nificant uptake of NT-conjugated fluorophores was observed at 100
nM extracellular concentration. This is consistent with other stud-
ies in which branched NT-conjugated drugs have EC50 values in the
range of 100–400 nM [8]. Low levels of free fluorescein uptake
observed here are consistent with other studies, with the applied
concentration being significantly lower than the observed Km for
uptake into Caco-2 cells of 7.7 mM [31].
Following the demonstration that in differentiated Caco-2
monolayers NT-conjugated fluorophores internalise through
receptor-mediated endocytosis, subsequent work established
whether NT-conjugated fluorophores have the capacity to translo-
cate across intestinal polarised monolayers, which, to our knowl-
edge, is the first time that neurotensin has been investigated for
such purpose. To achieve successful systemic drug delivery
through the gastrointestinal mucosa, the therapeutic must be
effectively internalised into epithelial cells from the gastrointesti-
nal lumen and released at the basal side. Owing to their physico-
chemical characteristics (molecular size), NT-conjugated
fluorophores are not expected to be absorbed across the epithe-
lium by diffusion/partitioning into epithelial membranes. Rather,
macromolecules generally traverse the epithelium by transcytosis
(paracellular space is considered inadequate for molecules over
1000 Da). Following internalisation into epithelial cells, the fate
of the cargo is dependent on the cell sorting machinery, with the
material most likely undergoing a mixture of recycling, deliveryto late endosomes and lysosomes, or transcytosis. Fig. 7 shows that
both F-NT and GFP-NT traverse differentiated Caco-2 monolayers
significantly more efficiently than the respective unconjugated flu-
orophores and in a concentration-dependent manner. Transport
process saturation was apparent, similarly to the previously
reported behaviour of IgG in airway epithelial monolayers [32].
This likely correlates with the internalisation of NT receptors,
which is an established desensitisation mechanism for GPCRs.
Notably, F-NT transport across differentiated Caco-2 monolayers
was markedly higher than GFP-NT, which suggests an effect by
the size of the cargo conjugated to NT. Given previous data [18]
it is also possible that the NT-conjugated cargoes will escape the
lysosomal pathway, increasing the likelihood of effective drug
delivery. Although NT receptors are expressed in the brain, it is
likely that many of the NT-macromolecular drug fusions will be
too large to cross the blood-brain barrier, thus eliminating a poten-
tially significant off-target effect.
In order to best leverage NTS1 as a drug targeting system, it is
highly desirable to have a comprehensive understanding of its
cargo limitations and intracellular trafficking. Overall, this work
indicates efficient and receptor expression-dependent uptake of
NT-conjugated fluorophores by HEK293 and Caco-2 cells, with
NTS1 demonstrating potential for uptake of a range of molecular
weight therapeutics following oral administration. The size depen-
dence of the cargo is clear, but it is still possible to deliver rela-
tively large macromolecules (GFP has a molecular weight of
Fig. 7. Apical-to-basolateral transport of NT-conjugated fluorophores in differentiated Caco-2 cell monolayer (21-day filter culture). (A) Transport of F-NT following
application at 20 nM, 50 nM or 100 nM F-NT alone or in combination with 100x free NT to the apical side of the monolayers. 100 nM F alone was used as a negative control.
Transport was measured after 180 min. (B) Transport of GFP-NT following application at 100 nM, 500 nM or 1 lM alone or combination 100 nM GFP-NT + 100x excess free NT
to the apical side of the monolayers. 1 lM GFP alone was used as a negative control. Transport was measured after 180 min. (C) Time course of F-NT transport as described in
(A). (D) Time course of GFP-NT transport as described in (B). Data points are representative of the mean of n = 3 independent experiments and error bars are representative
of ± SD.
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GPCRs assuming a common internalisation mechanism. Further
work will focus on characterising the method of internalisation,
specifically whether drug-ligand conjugates utilise a different
internalisation pathway to the ligand alone, as found with B12-
conjugated nanoparticles [33], as well as exploring the upper limit
of the size of cargo. In addition, the use of more stable analogies of
neurotensin will be explored to enhance the translation of these
findings to the clinical environment.Acknowledgements
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